Seromics: A New Frontier of Immune Biomarkers and Druggable Target Discovery

It is already clear that each individual’s serome is incredibly unique, complex, and yet accessible via proteome microarrays (HuProt), phage-display immunoprecipitation sequencing (PhIP-Seq, HuScan, VirScan), and other new synthetic biology platforms. Seromics experiments have revealed a viral-induced autoimmune cause of multiple sclerosis, pre-treatment autoantibodies associated with checkpoint blockade immunotherapy outcomes, and the demonstration that autoantibodies can mimic inborn errors of immunity – genetic-knockout-like phenotypes only discoverable via antibody profiling.